Cargando…
International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluatio...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830510/ https://www.ncbi.nlm.nih.gov/pubmed/33466893 http://dx.doi.org/10.3390/ijerph18020670 |
_version_ | 1783641431857954816 |
---|---|
author | Jung, Jae Ho Kim, Dae Jung Suh, Kangho You, Jaeeun Lee, Je Ho Joung, Kyung In Suh, Dong Churl |
author_facet | Jung, Jae Ho Kim, Dae Jung Suh, Kangho You, Jaeeun Lee, Je Ho Joung, Kyung In Suh, Dong Churl |
author_sort | Jung, Jae Ho |
collection | PubMed |
description | Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluation’ scheme to expedite patient access to oncology drugs. Methods: This study included 34 anticancer drugs, which were reimbursed between 1 January 2007 and 31 December 2017. The unit price and sales volume of the study drugs were collected from eight countries and IQVIA data, respectively. The prices were adjusted to estimate the ex-factory prices using the discount/rebate rate suggested by the Health Insurance Review Agency (HIRA). The four price indices of Laspeyres, Paasche, Fisher, and the unweighted index were calculated using the price in each country, the average price, and lowest price among the study countries. Each currency was converted using the currency exchange rate and purchasing power parity (PPP). The budget impact of implementing the proposed pre-listing and post-evaluation scheme on payers was calculated. Results: Based on the currency exchange rate, anticancer drug prices were higher in other countries (index range: 1.05–2.78) compared to Korea. The prices in Korea were similar to countries with the lowest prices. When the PPP was applied, prices were higher in the US, Germany, Italy, and Japan than in Korea (range: 1.10–2.13); however, the prices were lower in the UK, France, and Switzerland than in Korea (range: 0.72–0.99). The financial burden of implementing the pre-listing and post-evaluation scheme was calculated at 0.83% of the total anticancer drug sales value in Korea from 2013–2017. Conclusions: The prices of anticancer drugs in Korea were similar to the lowest prices among the seven other study countries. A pre-listing and post-evaluation scheme should be considered to improve patient access to novel anticancer drugs by reducing the reimbursement review time and uncertainties. |
format | Online Article Text |
id | pubmed-7830510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78305102021-01-26 International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility Jung, Jae Ho Kim, Dae Jung Suh, Kangho You, Jaeeun Lee, Je Ho Joung, Kyung In Suh, Dong Churl Int J Environ Res Public Health Article Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluation’ scheme to expedite patient access to oncology drugs. Methods: This study included 34 anticancer drugs, which were reimbursed between 1 January 2007 and 31 December 2017. The unit price and sales volume of the study drugs were collected from eight countries and IQVIA data, respectively. The prices were adjusted to estimate the ex-factory prices using the discount/rebate rate suggested by the Health Insurance Review Agency (HIRA). The four price indices of Laspeyres, Paasche, Fisher, and the unweighted index were calculated using the price in each country, the average price, and lowest price among the study countries. Each currency was converted using the currency exchange rate and purchasing power parity (PPP). The budget impact of implementing the proposed pre-listing and post-evaluation scheme on payers was calculated. Results: Based on the currency exchange rate, anticancer drug prices were higher in other countries (index range: 1.05–2.78) compared to Korea. The prices in Korea were similar to countries with the lowest prices. When the PPP was applied, prices were higher in the US, Germany, Italy, and Japan than in Korea (range: 1.10–2.13); however, the prices were lower in the UK, France, and Switzerland than in Korea (range: 0.72–0.99). The financial burden of implementing the pre-listing and post-evaluation scheme was calculated at 0.83% of the total anticancer drug sales value in Korea from 2013–2017. Conclusions: The prices of anticancer drugs in Korea were similar to the lowest prices among the seven other study countries. A pre-listing and post-evaluation scheme should be considered to improve patient access to novel anticancer drugs by reducing the reimbursement review time and uncertainties. MDPI 2021-01-14 2021-01 /pmc/articles/PMC7830510/ /pubmed/33466893 http://dx.doi.org/10.3390/ijerph18020670 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jung, Jae Ho Kim, Dae Jung Suh, Kangho You, Jaeeun Lee, Je Ho Joung, Kyung In Suh, Dong Churl International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility |
title | International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility |
title_full | International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility |
title_fullStr | International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility |
title_full_unstemmed | International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility |
title_short | International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility |
title_sort | international price comparisons of anticancer drugs: a scheme for improving patient accessibility |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830510/ https://www.ncbi.nlm.nih.gov/pubmed/33466893 http://dx.doi.org/10.3390/ijerph18020670 |
work_keys_str_mv | AT jungjaeho internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility AT kimdaejung internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility AT suhkangho internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility AT youjaeeun internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility AT leejeho internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility AT joungkyungin internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility AT suhdongchurl internationalpricecomparisonsofanticancerdrugsaschemeforimprovingpatientaccessibility |